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Reply to Eisen and Denholm,
Dauchy et al, Fierer, and
Nguyen and Jones
We appreciate the opportunity to reply
to the letters of Fierer [1], Eisen and
Denholm [2], Dauchy et al [3], and
Nguyen and Jones [4]. We are also glad
that the publication of the Infectious Dis-
eases Society of America (IDSA) guide-
lines on prosthetic joint infection (PJI)
has prompted additional discussion and
hope that this eventually manifests as
further research [5].
Fierer [1] raises the important question
of rifampin dosing in PJI due to suscepti-
ble staphylococci treated with debride-
ment and retention. We recommended
the dose as outlined in the only random-
ized clinical trial to address this issue [6].
In that trial, a dose of 450 mg orally
twice daily was used initially and de-
creased to 300 mg orally twice daily if
toxicity occurred that did not require
drug discontinuation. With oral rifampin
doses of 300 mg or 450 mg, peak concen-
trations of 4.0 µg/mL or 6 µg/mL, respec-
tively, are reached. The trough level of
both doses is >0.25 µg/mL at 12 hours
(half-life: 2.5 hours). The 600-mg dose
results in a peak of 10 µg/mL, with a
trough level at 24 hours of about 0.08 µg/
mL (half-life: 3 hours) [7]. In view of
the minimum inhibitory concentration
(MIC) values of Staphylococcus aureus
(0.008–0.15 µg/mL, MIC 90% [MIC90]:
0.015 µg/mL) and Staphylococcus epider-
midis (0.004–0.15 µg/mL, MIC90: 0.015
µg/mL), all these regimens may be ade-
quate [8]. The dose of 300–450 mg orally
twice daily as well as 600 mg orally once
daily was also recently recommended in
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the IDSA guidelines for treatment of
methicillin-resistant S. aureus [9].
Eisen and Denholm [2] raise the ques-
tion of the A1-level ranking of the recom-
mendation for the use of rifampin for
staphylococcal PJI treated with debride-
ment and retention. We followed the
ranking system as recommended by IDSA
and the Canadian Task Force on the Pe-
riodic Health Examination [5]. That
document states there must be at least 1
randomized trial to give it a rank of A1.
We regret the typographical error in
table 1 of the PJI guidelines [5], which
states >1 rather than ≥1. The panel be-
lieves there is ample evidence to support
the use of rifampin for this indication as
outlined in the PJI guidelines.
Dauchy et al [3] raise multiple ques-
tions. The panel did not recommend
cutoffs for C-reactive protein and sedi-
mentation rate, as different authors have
used different cutoffs. We believe what is
abnormal for these tests should be left to
the clinician and the laboratory they are
utilizing. We state in the footnote of table
2 [5] that the vancomycin dose should be
based on serum levels and that optimal
serum levels will depend on the patho-
gen. In addition, optimal serum levels are
unknown if local antimicrobial therapy is
used, such as when a spacer is used
during 2-stage exchange or when vanco-
mycin is used in conjunction with rifam-
pin. We believe we clariﬁed the issue of
duration of therapy as best we could
based on the available evidence and
expert opinion. We clearly stated where
there was and was not consensus regard-
ing the use of chronic oral suppression
given the data available for the various
surgical procedures including debride-
ment and retention and 1-stage ex-
change. We think more research is
warranted to clarify this issue further and
stated so in the “research gaps” section of
the guidelines. It is true we did not make
a deﬁnitive recommendation for 1-stage
exchange for joint arthroplasties other
than for hip arthroplasty. We agree with
the authors that, since our literature
review was completed, additional infor-
mation has become available to suggest
that 1-stage exchange for total knee ar-
throplasty infection may be useful [10,
11]. We look forward to additional infor-
mation becoming available.
Last, Nguyen and Jones [4] raise the
important question about the optimal
dose of ceftriaxone for the treatment
of oxacillin- and ceftriaxone-susceptible
staphylococci based on the oxacillin
MIC. We understand the argument for
the 2- to 4-g dose of ceftriaxone every
12–24 hours as outlined by the authors
in their letter but also recognized, based
on the references cited by the authors as
well as additional references included in
the PJI guidelines [12, 13], that a dose of
1–2 g every 24 hours has been success-
fully used by investigators to treat PJI
due to susceptible staphylococci. It was
on the basis of this information that we
recommended a dosing range of 1–2 g
every 24 hours. We also clearly state that
we could not reach consensus about the
use of ceftriaxone in general for the treat-
ment ofmethicillin-sensitive, ceftriaxone-
susceptible staphylococci. Certainlywhere
ceftriaxone has formed a signiﬁcant com-
ponent of intravenous antibiotic therapy,
we are aware that it was commonly used
to support outpatient parenteral antibi-
otic therapy (OPAT) and would mainly
have been preceded by a period of high-
dose anti-staphylococcal penicillin thera-
py in the immediate postoperative period
and for some days prior to patient dis-
charge into a OPAT program. Initiating
treatment with ceftriaxone in the face of
high bacterial burdens may pose differ-
ent risks to doing so after a formal surgi-
cal debridement either as part of
a debridement and implant retention
(DAIR) procedure or at revision surgery,
when the bacterial burden has been dra-
matically reduced. Furthermore, when
used as part of a DAIR strategy, ceftriax-
one was itself followed by extended
therapy with, usually, a ﬂuoroquinolone
and rifampin. These complexities, and
the fact that failures of treatment have
been seen to occur both during therapy
(of any kind) and when antibiotics are
stopped, do make it hard to be certain
whether the theoretical concerns from
Nguyen and Jones, based as they are
mainly on MIC data, give a genuine
cause for concern in the real world.
We agree that clinicians should con-
sider all information, including the
guidelines and the information outlined
by Nguyen and Jones [4] (as well as the
fact that pharmacokinetic/pharmacody-
namic predications may not reﬂect the
dosage of a particular drug required in
the setting of the use of combination
therapy with rifampin or procedures
where antibiotic-impregnated spacers are
used), when they are making treatment
decisions for individual patients.
As with many aspects of the diagnosis
and treatment of PJI, there may be multi-
ple ways to successfully manage these
most difﬁcult infections; additional re-
search is needed to deﬁne optimal treat-
ment strategies.
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